The latest ann is getting some positive broker sentiment. This...

The latest ann is getting some positive broker sentiment. This was reported today on NineMSN. I hear also ABN Amro about to update their report and recomendation

RBS Australia rates AVX, 0.120, +0, +0%) as Buy - The broker notes the company is to close its Phase III study for ATC early, which is likely to reduce costs and shorten the development timeline for the HIV drug. Results should be announced in the first quarter of next year and the broker notes there are other trials results due by the end of this year as well as an announcement on a licensing agreement with Tibotec Pharmaceuticals, al of which are potential positive catalysts for the stock. Given the scope for good news the broker retains its Buy rating. More